Bliss Biopharmaceutical Entered into a Clinical Trial Collaboration Agreement with Eisai for BB-1701 to Treat Cancers
- BlissBio will receive up front & milestones. If Eisai exercises its option, BlissBio will also receive an option exercise fee, ~$2B in development & commercial milestones along with royalties. Both companies will conduct co-development activities related to BB-1701 through an option period
- Upon the option exercise, Eisai to get a right globally (excl. Greater China) to develop & commercialize BB-1701, eribulin-payload-based ADC directed against HER2 which is currently being studied in the P-I/II studies in the US & China
- The therapy will provide a safer & more effective treatment regimen for LA/metastatic HER2-expressing solid tumors & has unique MoA incl. potent bystander effect & ICD activity
Ref: Gilead | Image: Bliss Biopharmaceutical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.